Standard BioTools Files 8-K on Operations & Financial Condition

Ticker: LAB · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1162194

Standard Biotools Inc. 8-K Filing Summary
FieldDetail
CompanyStandard Biotools Inc. (LAB)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-filing

TL;DR

**Standard BioTools just dropped an 8-K with financial updates, so check it out.**

AI Summary

Standard BioTools Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, along with Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates the company is providing an update on its financial performance and other material information. For investors, this matters because it offers a glimpse into the company's current financial health and any significant developments that could impact its stock price, allowing them to make informed decisions.

Why It Matters

This filing provides investors with crucial, up-to-date financial information, which is essential for evaluating the company's performance and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present new risks, though the content of the disclosed financials could reveal risks.

Analyst Insight

A smart investor would review the full content of the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' once they become available to understand the specific financial performance and any material changes reported by Standard BioTools Inc. This filing itself is a procedural update, but the underlying financial data is key.

Key Players & Entities

  • Standard BioTools Inc. (company) — the registrant filing the 8-K
  • Delaware (company) — state of incorporation for Standard BioTools Inc.
  • 001-34180 (dollar_amount) — Commission File Number for Standard BioTools Inc.
  • 77-0513190 (dollar_amount) — I.R.S. Employer Identification No. for Standard BioTools Inc.
  • 2 Tower Place, Suite 2000, South San Francisco, California 94080 (company) — address of principal executive offices for Standard BioTools Inc.
  • 650-266-6000 (dollar_amount) — telephone number for Standard BioTools Inc.
  • January 8, 2024 (person) — date of earliest event reported

FAQ

What is the purpose of this 8-K filing by Standard BioTools Inc.?

The 8-K filing by Standard BioTools Inc. on January 8, 2024, is to report on 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Financial Statements and Exhibits,' as indicated in the 'ITEM INFORMATION' section of the filing.

What is the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024, as stated under 'Date of report (Date of earliest event reported) : January 8, 2024'.

Where are the principal executive offices of Standard BioTools Inc. located?

The principal executive offices of Standard BioTools Inc. are located at '2 Tower Place, Suite 2000, South San Francisco, California 94080'.

What is the Commission File Number for Standard BioTools Inc.?

The Commission File Number for Standard BioTools Inc. is '001-34180', as listed in the filing.

Under which act is this current report filed?

This current report is filed 'Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934'.

Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-08 08:39:45

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share LAB Nasdaq Global Select Ma

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Standard BioTools Inc. (the "Company") issued a press release which included information with respect to certain preliminary financial results of the Company and SomaLogic, Inc. for the three months and fiscal year ended December 31, 2023. The press release is attached hereto as Exhibits 99.1 and incorporated herein by reference.

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, the Company updated its investor presentation, which the Company expects to use in connection with general corporate presentations and will be made available on the Company's website or distributed by the Company in hardcopy or electronic form. The investor presentation is attached hereto as Exhibits 99.2 and incorporated herein by reference. The investor presentation is current as of January 8, 2024, and the Company disclaims any obligation to update the investor presentation after such date.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Standard BioTools Inc., dated January 8, 2024. 99.2 Investor Presentation issued by Standard BioTools Inc., dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.